Versant Capital Management Inc Increases Holdings in Pfizer Inc. $PFE

Versant Capital Management Inc increased its stake in Pfizer Inc. (NYSE:PFE) by 179.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 31,389 shares of the biopharmaceutical company’s stock after acquiring an additional 20,167 shares during the period. Versant Capital Management Inc’s holdings in Pfizer were worth $800,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Curio Wealth LLC boosted its holdings in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the period. Harbor Asset Planning Inc. purchased a new position in Pfizer during the second quarter worth $29,000. Howard Hughes Medical Institute bought a new position in Pfizer during the second quarter valued at $30,000. Darwin Wealth Management LLC bought a new position in Pfizer during the second quarter valued at $32,000. Finally, Evelyn Partners Asset Management Ltd purchased a new stake in Pfizer in the 2nd quarter worth about $33,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PFE. UBS Group started coverage on shares of Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target on the stock. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $27.88.

Pfizer Trading Up 1.6%

NYSE PFE opened at $25.56 on Thursday. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The company has a market capitalization of $145.32 billion, a price-to-earnings ratio of 14.86 and a beta of 0.47. The company’s 50-day simple moving average is $25.31 and its two-hundred day simple moving average is $24.98.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.